Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients

Kanno, Chihiro; Kojima, Momoyo; Tezuka, Yu; Yaginuma, Sadanoshin; Kanaya, Yoshiaki; Kaneko, Tetsuharu

doi:10.1016/j.bone.2023.116892

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of MRONJ in patients with prostate cancer (5–39%) has been reported to be higher than in patients with other cancers 1 , 11 , 17 , 18 . Patients with advanced prostate cancer now achieve prolonged survival owing to novel drugs and treatment modalities 19 – 21 .…”

Section: Introductionmentioning

confidence: 99%

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Tani,

Hatano,

Yoshimura

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of medication-related osteonecrosis of the jaw (MRONJ). The safety of long-term BMA administration in clinical practice remains unclear. We aimed to determine the cumulative incidence and risk factors of MRONJ. One hundred and seventy-nine patients with prostate cancer with bone metastases treated with BMA at our institution since 2008 were included in this study. Twenty-seven patients (15%) had MRONJ during the follow-up period (median, 19 months; interquartile range, 9–43 months). The 2-year, 5-year, and 10-year cumulative MRONJ incidence rates were 18%, 27%, and 61%, respectively. Multivariate analysis identified denosumab use as a risk factor for MRONJ, compared with zoledronic acid use (HR 4.64, 95% CI 1.93–11.1). Additionally, BMA use at longer than one-month intervals was associated with a lower risk of MRONJ (HR 0.08, 95% CI 0.01–0.64). Furthermore, six or more bone metastases (HR 3.65, 95% CI 1.13–11.7) and diabetes mellitus (HR 5.07, 95% CI 1.68–15.2) were risk factors for stage 2 or more severe MRONJ. MRONJ should be considered during long-term BMA administration in prostate cancer patients with bone metastases.

show abstract

Section: Introductionmentioning

confidence: 99%

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Tani,

Hatano,

Yoshimura

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The incidence of ARONJ in patients with cancer is higher than that in patients without cancer. This is particularly the case in prostate cancer, where the incidence is reported to be 5-15%, which is higher than that in other cancers [1,15,16]. Patients with advanced prostate cancer now achieve prolonged survival owing to novel drugs and treatment modalities [17,18,19].…”

Section: Introductionmentioning

confidence: 99%

Cumulative Incidence and Risk Factors for Anti-Resorptive Agent-Related Osteonecrosis of the Jaw during Long-Term Prostate Cancer Management

Tani,

Hatano,

Yoshimura

et al. 2024

Preprint

View full text Add to dashboard Cite

Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of anti-resorptive agent-related osteonecrosis of the jaw (ARONJ). The safety of long-term BMA administration in clinical practice remains unclear. We aimed to determine the cumulative incidence and risk factors of ARONJ. One hundred and seventy-nine patients with prostate cancer with bone metastases treated with BMA at our institution since 2008 were included in this study. Twenty-seven patients (15%) had ARONJ during the follow-up period (median, 19 months; interquartile range, 9–43 months). The 2-year, 5-year, and 10-year cumulative ARONJ incidence rates were 18%, 27%, and 61%, respectively. Multivariate analysis identified denosumab use as a risk factor for ARONJ, compared with zoledronic acid use (HR 4.64, 95% CI 1.93–11.1). Additionally, BMA use at longer than one-month intervals was associated with a lower risk of ARONJ (HR 0.08, 95% CI 0.01–0.64). Furthermore, six or more bone metastases (HR 3.65, 95% CI 1.13–11.7) and diabetes mellitus (HR 5.07, 95% CI 1.68–15.2) were risk factors for stage 2 or more severe ARONJ. ARONJ should be considered during long-term BMA administration in prostate cancer patients with bone metastases.

show abstract

Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients

Cited by 2 publications

References 16 publications

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Cumulative Incidence and Risk Factors for Anti-Resorptive Agent-Related Osteonecrosis of the Jaw during Long-Term Prostate Cancer Management

Contact Info

Product

Resources

About